<DOC>
	<DOCNO>NCT00980213</DOCNO>
	<brief_summary>Patient receive sunitinib accord clinician 's independent decision first-line treatment advance renal cell carcinoma ( RCC ) ask informed consent . Treatment sunitinib start end solely treat clinician patient independent discretion . Consenting patient prospectively answer standardize quality life questionnaire ( 15D , EQ-5D ) treatment . Data health care resource utilisation collect prospectively ( outpatient visit , hospital stay , concomitant drug , investigation , sick-leaves , travel ) . In addition , treatment failure anti-cancer drug , hospital stay date death record . The health economic data sunitinib treatment length sunitinib treatment compare correspond previously publish data collect retrospectively patient condition treat IFN-alfa . Stepwise regression analysis use explore whether patient tumor characteristic explain potential variation treatment duration cost explain treatment . Health-related quality life ( HRQoL ) data present descriptive data compare age-standardized general population . At least four major Finnish oncology center consent participate study . The inclusion time approximately 24 month , study time approximately 48 month . Eighty patient include .</brief_summary>
	<brief_title>Evaluation Cost Effectiveness Sunitinib Compared Interferon-Alfa Finland</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Clinically indicate firstline sunitinib treatment advance RCC . Informed consent obtain . Unable complete HRQoL form . Not consent collect register data .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>renal cell cancer</keyword>
	<keyword>sunitinib</keyword>
	<keyword>cost</keyword>
	<keyword>quality life</keyword>
</DOC>